Evidence & regulatory context
- Mechanism
- Amphibian skin-derived wound-healing peptide; not in ChEMBL (peptide, preclinical). No ClinicalTrials.gov record (searched, not assumed); the wound-healing-peptide query returned only unrelated oncology studies and Granexin gel (an alpha-connexin carboxyl-terminal peptide), excluded as a different molecule.
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundBALB/cFemalen = n = 6 mice per group for the wound model and histologyTopical application to the wound20 microlitres per wound at 200 micrograms/mLTreatment began on the day of wounding (day 0)
Model: Full-thickness dorsal skin wound created with an 8 mm biopsy punch under sodium pentobarbital anaesthesia
Topical Ot-WHP significantly accelerated full-thickness wound repair relative to PBS, with healing rates of 67.7, 81.5, 84.8 and 88.5 per cent at days 2, 4, 6 and 8, comparable to the AH90 and EGF positive controls, while scrambled peptide had no effect. Histology showed improved epidermal regenera…
Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.